Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Aimee S. Payne, MD, PhD

Aimee S. Payne, MD, PhD Physician

Albert M. Kligman Associate Professor of Dermatology

Dr. Payne is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Dermatology

Programs & Centers:

Board Certification:

  • Dermatology, 2005

Clinical Expertise:

  • Dermatitis Herpetiformis (Duhring's Disease)
  • Mole Check
  • Pemphigus
  • Skin Cancer

Description of Clinical Expertise

Medical Dermatology
Blistering Skin Diseases

Practice Locations and Appointments

  • Penn Dermatology Perelman

    Perelman Center for Advanced Medicine South Pavilion, 1st Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Vetrans Choice Program (6/2018 Not Active)

Education and Training

Medical School: Washington University
Residency: Pennsylvania Hospital
Residency: Hospital of the University of Pennsylvania

Memberships

American Academy of Dermatology, National American Dermatological Association, National American Society for Clinical Investigation, National Board of Scientific Counselors, NIH/NIAMS, National Dermatology Foundation, National Deutsche Forschungsgemeinschaft, International International Pemphigus and Pemphigoid Foundation, International NIH study section ad-hoc reviewer, ZRG1/ACTS, National Society for Investigative Dermatology, International

Hospital Affiliation

Dr. Payne is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Research Interests:
Genetic and functional characterization of human anti-desmoglein B cell repertoires
Targeted therapy for pemphigus
Regulation of desmosome adhesion

Key words: autoimmunity, human immunology, CAR T cells, adoptive immunotherapy, cell adhesion, dermatology, skin, cadherin, p38 MAPK

Description of Research:
Pemphigus vulgaris is a potentially fatal disorder in which autoantibodies against desmosomal cell adhesion molecules known as desmogleins cause blistering of the skin and mucous membranes. Our laboratory is interested in better understanding pathogenic mechanisms in this model organ-specific autoimmune disease, from both the immunologic and cell biologic perspectives.

A fundamental question in organ-specific autoimmune disease is why the immune system breaks tolerance against only a limited number of self-antigens. We have cloned B cell repertoires from pemphigus vulgaris patients to understand how they developed desmoglein autoreactivity. We identified shared VH1-46 gene usage in anti-desmoglein 3 B cells from different pemphigus patients and defined acidic amino acid residues that are necessary and sufficient to confer desmoglein 3 autoreactivity. We also identified common as well as divergent features of the B cell response to the self-antigen desmoglein 3 and the rotavirus VP6 antigen, which suggests shared VH gene usage in the immune response to foreign and self antigens as a potential basis for triggering pathologic autoimmune reactions. Ongoing projects aim to better understand the features of the autoimmune response in pemphigus, including isotype-specific lineage tracing of pemphigus autoantibody repertoires and characterization of the B cell subsets that contribute to autoimmunity in pemphigus.

Our laboratory has also elucidated the cell regulatory pathways that promote desmosome adhesion. We have shown that the p38 MAPK/MK2 axis governs keratinocyte desmosomal adhesion and that inhibition of this pathway can ameliorate pemphigus skin blistering. We identified STAT3 as a key regulator of desmoglein 3 transcription in keratinocytes, which contributes to the rapid therapeutic effect of corticosteroids in pemphigus and may explain the loss of desmoglein 3 expression in advanced head and neck squamous cell cancers.

Ultimately, a better understanding of the shared structural elements of pemphigus B cell repertoires can lead to better targeted therapies for disease. Current methods for treating autoimmunity require general immune suppression to reduce antibody production, but this approach impairs protective immune responses, which can lead to potentially fatal infections and secondary cancers. We described a novel method for re-engineering chimeric antigen receptor T cells for targeted immunotherapy of pemphigus vulgaris. By using the pemphigus autoantigen desmoglein 3 as the extracellular domain of a chimeric autoantibody receptor (CAAR), we can direct a patient’s T cells to specifically seek out and kill the pemphigus-specific B cells, while sparing the good immune cells that protect from infection. We are currently in the process of moving CAAR technology forward to human clinical trials.

Lab personnel:
Xuming Mao, MD/PhD, senior research investigator
Eun Jung Choi, MS, lab manager and research specialist
Nina Ran, Masters in Translational Research thesis student
Jinmin Lee, PhD, postdoctoral fellow
Sangwook Oh, postdoctoral fellow
Carolyn Kushner (Penn medical student)
Adam Alghalith (Penn Class of 2020)
Daniel Lundgren (Penn Class of 2018)

Lab alumni (current position):
Preety M. Sharma, PhD (Associate Research Scientist, Columbia University)
Takeru Funakoshi, MD, PhD (Dermatology faculty, Keio University, Japan)
Luisa Lunardon, MD (Dermatology, Milan)
Arielle Nagler, MD (Dermatology faculty, New York University)
Michael Jeffrey Cho, PhD (Healthcare consultant)
Sara Farber, MD (Dermatology resident, University of Pennsylvania)
Courtney Rubin, MD (Dermatology resident, University of Pennsylvania)
Eric Mukherjee, MD, PhD (Yale internal medicine internship)
Christoph Ellebrecht, MD (Dermatology resident, University of Pennsylvania)

Other Penn Appointments:
Associate Director, Medical Scientist Training Program
Faculty Advisor, Association for Women Student MD-PhDs (AWSM)
Immunology Graduate Group
Cell and Molecular Biology Graduate Group

Selected Publications:

Mao X, Cho MJ, Ellebrecht CT, Mukherjee EM, Payne AS: Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes JCI Insight 2 (9): e92253,2017.

Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M: Pemphigus Nature Reviews Disease Primers 11 (3): 17026,2017.

Ellebrecht CT, Payne AS: Setting the target for pemphigus vulgaris therapy JCI Insight 2 (5): e92021,2017.

Chen J, Zheng Q, Hammers CM, Ellebrecht CT, Mukherjee EM, Tang HY, Lin C, Yuan H, Pan M, Langenhan J, Komorowski L, Siegel DL, Payne AS, Stanley JR: Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B cell genetics Cell Reports 18 (1): 237-247,2017.

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Science 353 : 179-184,2016.

Cho MJ, Ellebrecht CT, Hammers CM, Mukherjee EM, Sapparapu G, Boudreaux CE, McDonald SM, Crowe JE, Jr., Payne AS.: Determinants of VH1-46 cross-reactivity to pemphigus vulgaris autoantigen desmoglein 3 and rotavirus antigen VP6 J. Immunol. 197 (4): 1065-73,2016.

Cho MJ, Lo ASY, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS: Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients Nature Commun. 5 : 4167,2014.

Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS: Subcutaneous veltuzumab, a humanized anti-CD20 antibody, for treatment of refractory pemphigus vulgaris JAMA Dermatol. 150 : 1331-1335,2014.

Mao X, Li H, Sano Y, Gaestel M, Park JM, Payne AS.: MAPKAP kinase 2 (MK2)-dependent and independent models of blister formation in pemphigus vulgaris. J. Invest. Dermatol. 134 : 68-76,2014.

Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS.: Enrichment of total serum IgG4 in pemphigus patients Br.J.Dermatol. 167 : 1245-1253,2012.

View all publications

Academic Contact Info

1009 Biomedical Research Building
421 Curie Boulevard

Philadelphia, PA 19104
Phone: (215) 662-2737
Patient appointments: 800-789-7366 (PENN)

Related Links